ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Experiences Heavier than Usual Trading Volume

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Experiences Heavier than Usual Trading Volume

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Experiences Heavier than Usual Trading Volume

These firms have also modified their investment in ACAD. Proficio Capital Partners LLC added to its stake by buying 16 shares an increase of 72.7% from 12/31/2016 to 03/31/2017. Oppenheimer Asset Management Inc. purchased a new stake in ACADIA Pharmaceuticals during the first quarter valued at $161,000. Morgan Stanley trimmed its stake by shedding 2,151 shares a decrease of 5.9%. Norges Bank acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $24,050,000. BlackRock Inc. raised its stake in shares of ACADIA Pharmaceuticals by 2.9% in the second quarter. Glenn Baity, EVP AND GC disclosed the sale of 1,903 shares.

COPYRIGHT VIOLATION NOTICE: "PNC Financial Services Group Inc". PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company's stock worth $150,000 after buying an additional 2,548 shares during the period. Vanguard Group Inc. now owns 7,469,785 shares of the biopharmaceutical company's stock worth $256,812,000 after buying an additional 348,141 shares during the period.

Several large investors have recently bought and sold shares of the company.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, August 8th.

The closing price represents the final price that a stock is traded for on a trading day. Wells Fargo Mn has 0% invested in ACADIA Pharmaceuticals Inc. The market capitalization of the company is at $3.91 Billion. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. Its revenue totaled $20.02 million up 30.94% from the previous quarter. Next quarter's EPS is forecasted to be $-0.63 and the next full year EPS is anticipated to be $-1.91. The business's quarterly revenue was up 30400.0% compared to the same quarter past year.

Premier League relegation battle - Who will go down?
"For example, hopefully next season I will be here and we are not going to spend how we spent this season". We put our bodies in we made some important tackles and eventually we got the goal because we were patient.

Dallas Cowboys RB Ezekiel Elliott ready for 'long battle' over suspension
It's within his CBA-dictated power to go beyond that, but that doesn't mean his league partners have to agree with it. But Elliott and his representation plan to fight the suspension arduously.

Creative Planning Has $154000 Position in MGIC Investment Corporation (NYSE:MTG)
The company's net profit margin has achieved the current level of 35 percent and possesses 0 percent gross margin. World Asset Management Inc raised its position in MGIC Investment Corporation by 0.7% in the first quarter.

ACADIA Pharmaceuticals Inc. on 6/29/2017 reported its EPS as $-0.61 with the analysts projecting the EPS of the stock as $-0.56. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & worldwide copyright law. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of United States and worldwide trademark and copyright legislation. (NASDAQ:ACAD). Sivik Healthcare Ltd has invested 0.96% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in a report released on Wednesday. Zacks Investment Research raised ACADIA Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday, May 12th. Rodman & Renshaw reiterated a "buy" rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, May 22nd. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, April 14th. HC Wainwright restated a "buy" rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, May 10th. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 14,322 shares of the business's stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $30.00, for a total value of $1,142,910.00. Levin Capital Strategies, L.p. owns 21,912 shares with a value of $753,000. The company's institutional ownership is monitored at 99.2 percent.

HC Wainwright reiterated their buy recommendation on stocks of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a study report released on Wednesday. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders.

"Our commercial efforts continue to drive strong financial performance with solid market uptake for Nuplazid in patients with Parkinson's disease psychosis", said the company's President and Chief Executive Officer, Steve Davis. The hedge funds in our partner's database now hold: 119.51 million shares, up from 116.39 million shares in 2016Q3.

Latest News